Review Article
Rivaroxaban and Hemostasis in Emergency Care
Table 1
Change of prothrombin time in seconds (5–95% percentile) using various rivaroxaban doses and the STA Neoplastine CI Plus Assay [
2].
| Indication | Dose | PT at maximum plasma concentration (hours after ingestion) | PT at minimum plasma concentration (hours after ingestion) |
| Prevention of VTE | 10 mg od | 13–25 s (2–4 h) | Not studied | Treatment of VTE (first 3 weeks) | 15 mg bid | 17–32 s (2–4 h) | 14–24 s (8–16 h) | Treatment of VTE (after 3 weeks) | 20 mg od | 15–30 s (2–4 h) | 13–20 s (18–30 h) | Nonvalvular AF for stroke prevention | 20 mg od | 14–40 s (1–4 h) | 12–26 s (16–36 h) | Nonvalvular AF for stroke prevention (CrCl <50 mL/min) | 15 mg od | 10–50 s (1–4 h) | 12–26 s (16–36 h) |
|
|
AF: atrial fibrillation; bid: twice daily; CrCl: creatinine clearance; od: once daily; PT: prothrombin time; VTE: venous thromboembolism.
|